BR112018010635A2 - linhagens celulares estáveis para a produção retroviral - Google Patents
linhagens celulares estáveis para a produção retroviralInfo
- Publication number
- BR112018010635A2 BR112018010635A2 BR112018010635A BR112018010635A BR112018010635A2 BR 112018010635 A2 BR112018010635 A2 BR 112018010635A2 BR 112018010635 A BR112018010635 A BR 112018010635A BR 112018010635 A BR112018010635 A BR 112018010635A BR 112018010635 A2 BR112018010635 A2 BR 112018010635A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- retroviral
- cell lines
- relates
- acid sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
- C12N15/8673—Special methods for packaging systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Seal Device For Vehicle (AREA)
Abstract
a invenção se refere a uma célula de produção retroviral compreendendo sequências de ácidos nucleicos que codificam: proteínas gag e pol; proteína de envelopamento ou um substituto funcional da mesma; e o genoma de rna da partícula de vetor retroviral, em que as referidas sequências de ácidos nucleicos estão todas localizadas em um único local dentro do genoma da célula de produção retroviral. a invenção também se refere a vetores de ácidos nucleicos compreendendo uma origem de não-mamífera de replicação e capacidade para conter pelo menos 25 quilobases (kb) de dna, caracterizado por o referido vetor de ácido nucleico compreender sequências de ácidos nucleicos retrovirais codificando: proteínas gag e pol, e uma proteína env ou um substituto funcional da mesma. a invenção também se refere a uso e métodos que utilizam o referido vetor de ácido nucleico de modo a produzir um empacotamento retroviral estável e linhagens celulares produtoras.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1520761.6A GB201520761D0 (en) | 2015-11-24 | 2015-11-24 | Stable cell lines for retroviral production |
GBGB1609303.1A GB201609303D0 (en) | 2016-05-26 | 2016-05-26 | Stable cell lines for retroviral production |
PCT/EP2016/078336 WO2017089308A1 (en) | 2015-11-24 | 2016-11-21 | Stable cell lines for retroviral production |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018010635A2 true BR112018010635A2 (pt) | 2018-11-27 |
Family
ID=57354376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018010635A BR112018010635A2 (pt) | 2015-11-24 | 2016-11-21 | linhagens celulares estáveis para a produção retroviral |
Country Status (17)
Country | Link |
---|---|
US (3) | US20170145388A1 (pt) |
EP (2) | EP3380604B1 (pt) |
JP (1) | JP7098521B2 (pt) |
KR (1) | KR102091957B1 (pt) |
CN (1) | CN108291208A (pt) |
AU (1) | AU2016360763B2 (pt) |
BR (1) | BR112018010635A2 (pt) |
CA (1) | CA3006288A1 (pt) |
DE (1) | DE102016122316A1 (pt) |
ES (2) | ES2959326T3 (pt) |
FR (1) | FR3044016A1 (pt) |
GB (1) | GB2544892B (pt) |
IL (2) | IL259254A (pt) |
IT (1) | IT201600117326A1 (pt) |
RU (1) | RU2752498C2 (pt) |
SA (1) | SA518391623B1 (pt) |
WO (1) | WO2017089308A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7816612B2 (en) * | 2005-12-21 | 2010-10-19 | Ishida Co., Ltd. | Rotary measuring device |
EP3380605A1 (en) | 2015-11-24 | 2018-10-03 | GlaxoSmithKline Intellectual Property Development Limited | Transient transfection method for retroviral production |
GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
GB201715052D0 (en) | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
EP3696272A1 (en) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviral vector |
WO2021041322A1 (en) * | 2019-08-23 | 2021-03-04 | Lonza Walkersville, Inc. | Methods and constructs for production of lentiviral vector |
US20230026345A1 (en) * | 2019-12-18 | 2023-01-26 | Lonza Walkersville, Inc. | Methods and constructs for transient production of lentiviral vector |
GB202004371D0 (en) | 2020-03-26 | 2020-05-13 | Glaxosmithkline Ip Dev Ltd | CAR constructs |
GB202005096D0 (en) | 2020-04-07 | 2020-05-20 | Glaxosmithkline | Modified vectors for production of retrovirus |
CN113528515B (zh) * | 2020-04-22 | 2023-05-05 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas13a干预阻断病毒逆转录转座的技术 |
WO2021231884A1 (en) * | 2020-05-15 | 2021-11-18 | Ivexsol, Inc. | Compositions and methods for producing stable viral vector producer cells for cell and gene therapy |
CN112430582B (zh) * | 2020-12-04 | 2022-05-03 | 北京艺妙神州医药科技有限公司 | 一种慢病毒稳定包装细胞系及其制备方法 |
BR112023018987A2 (pt) | 2021-03-19 | 2023-12-05 | Glaxosmithkline Ip Dev Ltd | Receptores de antígenos quiméricos direcionados à claudina-3 e métodos de tratamento do câncer |
WO2022225973A1 (en) * | 2021-04-20 | 2022-10-27 | The Regents Of The University Of California | Packaging cells with targeted gene knockouts that improve retroviral vector titers |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
DK0835137T3 (da) * | 1995-06-27 | 2006-03-06 | Bavarian Nordic As | Indkapslede celler, som danner viruspartikler |
FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
AU4364700A (en) * | 1999-04-22 | 2000-11-10 | General Hospital Corporation, The | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
US6677155B1 (en) * | 1999-04-22 | 2004-01-13 | The General Hospital Corporation | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
CA2371946A1 (en) * | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
AU2001265187A1 (en) | 2000-05-30 | 2001-12-11 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
US6689601B2 (en) | 2000-09-01 | 2004-02-10 | E. I. Du Pont De Nemours And Company | High growth methanotropic bacterial strain |
US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE10111433A1 (de) * | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
IL157746A0 (en) | 2001-05-30 | 2004-03-28 | Chromos Molecular Systems Inc | Chromosome-based platforms |
US6835568B2 (en) | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
EP1504108B1 (en) * | 2002-02-01 | 2013-04-17 | Oxford Biomedica (UK) Limited | Lentiviral vector |
WO2004048582A2 (en) * | 2002-11-25 | 2004-06-10 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ati promoters |
EP1743028A2 (en) * | 2004-04-28 | 2007-01-17 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
EP1652932A1 (en) * | 2004-11-02 | 2006-05-03 | GBF Gesellschaft für Biotechnologische Forschung mbH | Method for the generation of virus producing cell lines and cell lines |
ES2357372T3 (es) * | 2004-11-24 | 2011-04-25 | Anaeropharma Science Inc. | Nuevo vector lanzadera. |
GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
EP2193879B1 (de) | 2008-12-05 | 2012-08-01 | Mikron Agie Charmilles AG | Werkzeugreinigung |
WO2012028681A1 (en) * | 2010-09-02 | 2012-03-08 | Molmed Spa | Stable production of lentiviral vectors |
US9273324B2 (en) * | 2010-12-05 | 2016-03-01 | Andrew S. Belmont | Recombinant gene expression |
WO2012170431A2 (en) * | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
FR2979919B1 (fr) * | 2011-09-12 | 2015-12-11 | Centre Nat Rech Scient | Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1 |
GB201202516D0 (en) * | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
EP2895611A4 (en) | 2012-09-14 | 2016-04-27 | Univ California | LENTIVIRAL VECTORS FOR STEM CELL GENE THERAPY OF SICKEN LEMENIA |
WO2014066700A1 (en) * | 2012-10-25 | 2014-05-01 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
US11078464B2 (en) * | 2013-08-30 | 2021-08-03 | Amgen Inc. | High titer recombinant AAV vector production in adherent and suspension cells |
GB2538321A (en) * | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Artificial chromosome for retroviral production |
GB2538324A (en) * | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Packaging cell line for retroviral production |
WO2017036733A1 (en) * | 2015-09-01 | 2017-03-09 | Philips Lighting Holding B.V. | Lighting device with a wireless communication antenna |
EP3380605A1 (en) * | 2015-11-24 | 2018-10-03 | GlaxoSmithKline Intellectual Property Development Limited | Transient transfection method for retroviral production |
-
2016
- 2016-11-21 RU RU2018122636A patent/RU2752498C2/ru active
- 2016-11-21 BR BR112018010635A patent/BR112018010635A2/pt active Search and Examination
- 2016-11-21 CN CN201680068650.7A patent/CN108291208A/zh active Pending
- 2016-11-21 DE DE102016122316.6A patent/DE102016122316A1/de not_active Withdrawn
- 2016-11-21 US US15/356,830 patent/US20170145388A1/en not_active Abandoned
- 2016-11-21 FR FR1661255A patent/FR3044016A1/fr active Pending
- 2016-11-21 EP EP16798512.6A patent/EP3380604B1/en active Active
- 2016-11-21 JP JP2018526799A patent/JP7098521B2/ja active Active
- 2016-11-21 GB GB1619643.8A patent/GB2544892B/en active Active
- 2016-11-21 ES ES19151187T patent/ES2959326T3/es active Active
- 2016-11-21 AU AU2016360763A patent/AU2016360763B2/en active Active
- 2016-11-21 CA CA3006288A patent/CA3006288A1/en active Pending
- 2016-11-21 KR KR1020187014237A patent/KR102091957B1/ko active IP Right Grant
- 2016-11-21 WO PCT/EP2016/078336 patent/WO2017089308A1/en active Application Filing
- 2016-11-21 IT IT102016000117326A patent/IT201600117326A1/it unknown
- 2016-11-21 EP EP19151187.2A patent/EP3489353B8/en active Active
- 2016-11-21 ES ES16798512T patent/ES2939617T3/es active Active
-
2018
- 2018-05-09 IL IL259254A patent/IL259254A/en unknown
- 2018-05-20 SA SA518391623A patent/SA518391623B1/ar unknown
- 2018-07-13 US US16/034,517 patent/US20180320147A1/en not_active Abandoned
-
2019
- 2019-12-18 US US16/718,791 patent/US20200123505A1/en not_active Abandoned
-
2021
- 2021-04-23 IL IL282603A patent/IL282603B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7098521B2 (ja) | 2022-07-11 |
DE102016122316A1 (de) | 2017-05-24 |
EP3489353B8 (en) | 2023-08-30 |
GB2544892B (en) | 2017-11-15 |
EP3489353C0 (en) | 2023-07-26 |
JP2018534937A (ja) | 2018-11-29 |
IL282603B (en) | 2022-05-01 |
US20200123505A1 (en) | 2020-04-23 |
IT201600117326A1 (it) | 2018-05-21 |
GB2544892A (en) | 2017-05-31 |
US20170145388A1 (en) | 2017-05-25 |
US20180320147A1 (en) | 2018-11-08 |
ES2939617T3 (es) | 2023-04-25 |
EP3489353B1 (en) | 2023-07-26 |
ES2959326T3 (es) | 2024-02-23 |
KR20180079351A (ko) | 2018-07-10 |
GB201619643D0 (en) | 2017-01-04 |
IL282603A (en) | 2021-06-30 |
WO2017089308A1 (en) | 2017-06-01 |
IL259254A (en) | 2018-07-31 |
FR3044016A1 (fr) | 2017-05-26 |
SA518391623B1 (ar) | 2022-10-30 |
RU2752498C2 (ru) | 2021-07-28 |
AU2016360763B2 (en) | 2020-11-05 |
CN108291208A (zh) | 2018-07-17 |
EP3489353A1 (en) | 2019-05-29 |
EP3380604A1 (en) | 2018-10-03 |
AU2016360763A1 (en) | 2018-05-31 |
RU2018122636A (ru) | 2019-12-25 |
KR102091957B1 (ko) | 2020-03-20 |
CA3006288A1 (en) | 2017-06-01 |
EP3380604B1 (en) | 2022-12-28 |
RU2018122636A3 (pt) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
CL2021002739A1 (es) | Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
WO2016160844A3 (en) | Methods and compositions for combinatorial barcoding | |
MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
CO2019006485A2 (es) | Anticuerpos y metodos de su utilizacion | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
BR112017016681A2 (pt) | vetor de coexpressão de vacina e moléculas coestimulatórias | |
WO2018132739A3 (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
BRPI0714495B8 (pt) | lentivírus deficiente para replicação recombinante pseudotipado | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
BR112015023489A2 (pt) | uso de rnas-guia truncads (tru - grnas) para aumentar a especificidade de edição de genoma com rna guiado | |
EP4249036A3 (en) | Methods and products for nucleic acid production and delivery | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
WO2015042308A3 (en) | Rna-based hiv inhibitors | |
BRPI1007214A2 (pt) | adaptador para sequenciar ácidos nucleicos, par de adaptadores, kit, construto de ácido nucleico, e, métodos para preparar um adaptador, um construto de ácido nucleico, e um construto de dequência, e para sequenciar ácido nucleico de fita dupla. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |